Compare Indoco Remedies with Cholamandalam Invest. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

INDOCO REMEDIES vs CHOLAMANDALAM INVEST. - Comparison Results

INDOCO REMEDIES     Change

Indoco Remedies is engaged in the manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs) for domestic as well as the international markets. The company's focus areas include anti-infective, respiratory, anti-diabetic... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    INDOCO REMEDIES CHOLAMANDALAM INVEST. INDOCO REMEDIES/
CHOLAMANDALAM INVEST.
 
P/E (TTM) x 128.4 3.4 3,736.6% View Chart
P/BV x 2.2 0.8 267.3% View Chart
Dividend Yield % 0.6 2.2 28.3%  

Financials

 INDOCO REMEDIES   CHOLAMANDALAM INVEST.
EQUITY SHARE DATA
    INDOCO REMEDIES
Mar-18
CHOLAMANDALAM INVEST.
Mar-18
INDOCO REMEDIES/
CHOLAMANDALAM INVEST.
5-Yr Chart
Click to enlarge
High Rs3171,480 21.4%   
Low Rs178971 18.3%   
Sales per share (Unadj.) Rs113.1351.9 32.1%  
Earnings per share (Unadj.) Rs4.562.4 7.2%  
Cash flow per share (Unadj.) Rs11.865.6 18.0%  
Dividends per share (Unadj.) Rs1.006.50 15.4%  
Dividend yield (eoy) %0.40.5 76.1%  
Book value per share (Unadj.) Rs73.2330.4 22.2%  
Shares outstanding (eoy) m92.15156.33 58.9%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x2.23.5 62.9%   
Avg P/E ratio x55.519.6 282.4%  
P/CF ratio (eoy) x21.018.7 112.3%  
Price / Book Value ratio x3.43.7 91.2%  
Dividend payout %22.410.4 214.9%   
Avg Mkt Cap Rs m22,830191,606 11.9%   
No. of employees `0005.56.8 80.6%   
Total wages/salary Rs m2,2095,416 40.8%   
Avg. sales/employee Rs Th1,910.18,127.4 23.5%   
Avg. wages/employee Rs Th405.0800.2 50.6%   
Avg. net profit/employee Rs Th75.51,441.2 5.2%   
INCOME DATA
Net Sales Rs m10,41955,006 18.9%  
Other income Rs m476 744.4%   
Total revenues Rs m10,46655,013 19.0%   
Gross profit Rs m1,34938,392 3.5%  
Depreciation Rs m677509 133.1%   
Interest Rs m23523,052 1.0%   
Profit before tax Rs m48414,838 3.3%   
Minority Interest Rs m016 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m725,100 1.4%   
Profit after tax Rs m4129,754 4.2%  
Gross profit margin %12.969.8 18.6%  
Effective tax rate %15.034.4 43.5%   
Net profit margin %4.017.7 22.3%  
BALANCE SHEET DATA
Current assets Rs m5,373121,800 4.4%   
Current liabilities Rs m4,157130,731 3.2%   
Net working cap to sales %11.7-16.2 -71.9%  
Current ratio x1.30.9 138.7%  
Inventory Days Days680-  
Debtors Days Days730 10,971,821.9%  
Net fixed assets Rs m6,2441,634 382.0%   
Share capital Rs m1841,564 11.8%   
"Free" reserves Rs m6,56641,876 15.7%   
Net worth Rs m6,75051,649 13.1%   
Long term debt Rs m1,233205,452 0.6%   
Total assets Rs m12,363395,684 3.1%  
Interest coverage x3.11.6 186.1%   
Debt to equity ratio x0.24.0 4.6%  
Sales to assets ratio x0.80.1 606.3%   
Return on assets %5.28.3 63.1%  
Return on equity %6.118.9 32.3%  
Return on capital %9.014.7 61.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m3,7620-   
Fx outflow Rs m1,143123 929.0%   
Net fx Rs m2,619-123 -2,127.8%   
CASH FLOW
From Operations Rs m1,227-75,922 -1.6%  
From Investments Rs m-1,360-1,229 110.6%  
From Financial Activity Rs m-38876,938 -0.5%  
Net Cashflow Rs m-521-213 244.2%  

Share Holding

Indian Promoters % 59.2 57.7 102.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 12.5 2.3 543.5%  
FIIs % 6.0 31.3 19.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.4 8.7 257.5%  
Shareholders   12,805 16,861 75.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare INDOCO REMEDIES With:   KITEX GARMENTS  WONDERLA HOLIDAYS  CENTURY PLYBOARDS  ADANI PORTS & SEZ  TALWALKARS BETTER VALUE  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

INDOCO REMEDIES Announces Quarterly Results (1QFY20); Net Profit Up 118.1% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, INDOCO REMEDIES has posted a net profit of Rs 22 m (up 118.1% YoY). Sales on the other hand came in at Rs 3 bn (up 16.2% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

INDOCO REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 43.3% (Quarterly Result Update)

Jun 6, 2019 | Updated on Jun 6, 2019

For the quarter ended March 2019, INDOCO REMEDIES has posted a net profit of Rs 116 m (down 43.3% YoY). Sales on the other hand came in at Rs 3 bn (down 6.5% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

CHOLAMANDALAM INVEST. Announces Quarterly Results (4QFY19); Net Profit Up 0.8% (Quarterly Result Update)

May 7, 2019 | Updated on May 7, 2019

For the quarter ended March 2019, CHOLAMANDALAM INVEST. has posted a net profit of Rs 3 bn (up 0.8% YoY). Sales on the other hand came in at Rs 19 bn (up 22.7% YoY). Read on for a complete analysis of CHOLAMANDALAM INVEST.'s quarterly results.

INDOCO REMEDIES 2017-18 Annual Report Analysis (Annual Result Update)

Mar 28, 2019 | Updated on Mar 28, 2019

Here's an analysis of the annual report of INDOCO REMEDIES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of INDOCO REMEDIES. Also includes updates on the valuation of INDOCO REMEDIES.

CHOLAMANDALAM INVEST. Announces Quarterly Results (3QFY19); Net Profit Up 21.7% (Quarterly Result Update)

Feb 1, 2019 | Updated on Feb 1, 2019

For the quarter ended December 2018, CHOLAMANDALAM INVEST. has posted a net profit of Rs 3 bn (up 21.7% YoY). Sales on the other hand came in at Rs 18 bn (up 30.4% YoY). Read on for a complete analysis of CHOLAMANDALAM INVEST.'s quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

INDOCO REMEDIES SHARE PRICE


Sep 20, 2019 (Close)

TRACK INDOCO REMEDIES

  • Track your investment in INDOCO REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON INDOCO REMEDIES

INDOCO REMEDIES 5-YR ANALYSIS

COMPARE INDOCO REMEDIES WITH

MARKET STATS